Texas organization grants $68.5M to Houston institutions for recruitment, research

cha-ching

Several Houston organizations have received millions from the Cancer Prevention and Research Institute of Texas. Photo via tmc.edu

Three prominent institutions in Houston will be able to snag a trio of high-profile cancer researchers thanks to $12 million in new funding from the Cancer Prevention and Research Institute of Texas.

The biggest recruitment award — $6 million — went to the University of Texas MD Anderson Center to lure researcher Xiling Shen away from the Terasaki Institute for Biomedical Innovation in Los Angeles.

Shen is chief scientific officer at the nonprofit Terasaki Institute. His lab there studies precision medicine, including treatments for cancer, from a “systems biology perspective.”

He also is co-founder and former CEO of Xilis, a Durham, North Carolina-based oncology therapy startup that raised $70 million in series A funding in 2021. Before joining the institute in 2021, the Stanford University graduate was an associate professor at Duke University in Durham.

Shen and Xilis aren’t strangers to MD Anderson.

In 2023, MD Anderson said it planned to use Xilis’ propriety MicroOrganoSphere (MOS) technology for development of novel cancer therapies.

“Our research suggests the MOS platform has the potential to offer new capabilities and to improve the efficiency of developing innovative drugs and cell therapies over current … models, which we hope will bring medicines to patients more quickly,” Shen said in an MD Anderson news release.

Here are the two other Cancer Prevention and Research Institute of Texas (CPRIT) awards that will bring noted cancer researchers to Houston:

$4 million to attract David Sarlah to Rice University from the University of Illinois, where he is an associate professor of chemistry. Sarlah’s work includes applying the principles of chemistry to creation of new cancer therapies.
$2 million to lure Vishnu Dileep to the Baylor College of Medicine from the Massachusetts Institute of Technology (MIT), where he is a postdoctoral fellow. His work includes the study of cancer genomes.

CPRIT also handed out more than $56.5 million in grants and awards to seven institutions in the Houston area. Here’s the rundown:

MD Anderson Cancer Center — Nearly $25.6 million
Baylor College of Medicine — Nearly $11.5 million
University of Texas Health Science Center at Houston — More than $6 million
Rice University — $4 million
University of Texas Medical Branch at Galveston — More than $3.5 million
Methodist Hospital Research Institute — More than $3.3 million
University of Houston — $1.4 million

Dr. Pavan Reddy, a CPRIT scholar who is a professor at the Baylor College of Medicine and director of its Dan L Duncan Comprehensive Cancer Care Center, says the CPRIT funding “will help our investigators take chances and explore bold ideas to make innovative discoveries.”

The Houston-area funding was part of nearly $99 million in grants and awards that CPRIT recently approved.

From Your Site Articles

Five Houston research centers have received funds from the Cancer Prevention and Research Institute of Texas in its most recent round of grants. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston cancer-fighting researchers granted over $30 million from statewide organization

just granted

The Cancer Prevention and Research Institute of Texas has again granted millions to Texas institutions. Across the state, cancer-fighting scientists have received 55 new grants totaling over $78 million.

Five Houston-area institutions — Baylor College of Medicine, the University of Houston, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Houston, and the The University of Texas MD Anderson Cancer Center — have received around $30 million of that grand total.

"These awards reflect CPRIT's established priorities to invest in childhood cancer research, address population and geographic disparities, and recruit top cancer research talent to our academic institutions," says Wayne Roberts, CPRIT CEO, in a news release. "I'm excited about all the awardees, particularly those in San Antonio, a region that continues expand their cancer research and prevention prowess. San Antonio is poised to have an even greater impact across the Texas cancer-fighting ecosystem."

Four grants went to new companies that are bringing new technologies to the market. Two companies with a presence in Houston — Asylia Therapeutics and Barricade Therapeutics Corp. — received grants in this category.

Last fall, CPRIT gave out nearly $136 million to Texas researchers, and, to date, the organization has granted $2.49 billion to Texas research institutions and organizations.

Here's what recent grants were made to Houston institutions.

Baylor College of Medicine

$900,000 granted for Feng Yang's research in targeting AKT signaling in MAPK4-high Triple Negative Breast Cancer (Individual Investigator Award)
$897,527 Hyun-Sung Lee's research for Spatial Profiling of Tumor-Immune Microenvironment by Multiplexed Single Cell Imaging Mass Cytometry (Individual Investigator Award)
$899,847 for Joshua Wythe's research in targeting Endothelial Transcriptional Networks in GBM (Individual Investigator Award)

University of Houston

$890,502 for Matthew Gallagher's research in Transdiagnostic Cognitive Behavioral Therapy for Smokers With Anxiety and Depression (Individual Investigator Research Award for Prevention and Early Detection)
$299,953 for Lorraine Reitzel's research in Taking Texas Tobacco Free Through a Sustainable Education/Training Program Designed for Personnel Addressing Tobacco Control in Behavioral Health Settings (Dissemination of CPRIT-Funded Cancer Control Interventions Award)

The University of Texas Medical Branch at Galveston

$1,993,096 for Abbey Berenson's research in maximizing opportunities for HPV vaccination in medically underserved counties of Southeast Texas (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas Health Science Center at Houston

$900,000 for Melissa Aldrich's research on "Can Microsurgeries Cure Lymphedema? An Objective Assessment" (Individual Investigator Award)
$900,000 for John Hancock's research in KRAS Spatiotemporal Dynamics: Novel Therapeutic Targets (Individual Investigator Award)
$900,000 for Nami McCarty's research in targeting Multiple Myeloma Stem Cell Niche (Individual Investigator Award)
$1.96 million for Paula Cuccaro's research in Expanding "All for Them": A comprehensive school-based approach to increase HPV vaccination through public schools (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas MD Anderson Cancer Center

$900,000 for Laurence Court's research in Artificial Intelligence for the Peer Review of Radiation Therapy Treatments
$900,000 for John deGroot's research in targeting MEK in EGFR-Amplified Glioblastoma (Individual Investigator Award)
$900,000 for Don Gibbons's research in Investigating the Role ofCD38 as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer (Individual Investigator Award)
$900,000 for John Heymach's research in Molecular Features Impacting Drug Resistance in Atypical EGFR Exon 18 and Exon 20 Mutant NSCLC and the Development of Novel Mutant- Selective Inhibitors (Individual Investigator Award)
$900,000 for Zhen Fan's research in Development of a Novel Strategy for Tumor Delivery of MHC-I-Compatible Peptides for Cancer Immunotherapy (Individual Investigator Award)
$900,000 for Jin Seon Im's research in off the shelf, Cord-Derived iNK T cells Engineered to Prevent GVHD and Relapse After Hematopoietic Stem Cell Transplantation (Individual Investigator Award)
$900,000 for Jae-il Park's research in CRAD Tumor Suppressor and Mucinous Adenocarcinoma (Individual Investigator Award)
$900,000 for Helen Piwnica-Worms's research in Single-Cell Evaluation to Identify Tumor-stroma Niches Driving the Transition from In Situ to Invasive Breast Cancer (Individual Investigator Award)
$898,872 for Kunal Rai's research in Heterogeneity of Enhancer Patterns in Colorectal Cancers- Mechanisms and Therapy (Individual Investigator Award)
$900,000 for Ferdinandos Skoulidis's research in Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBMl0-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy (Individual Investigator Award)
$887,713 for Konstantin Sokolov's research in High-Sensitivity 19F MRI for Clinically Translatable Imaging of Adoptive NK Cell Brain Tumor Therapy (Individual Investigator Award)
$900,000 for Liuqing Yang's research in Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance (Individual Investigator Award)
$1.44 million for Eugenie Kleinerman's research in Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions (Individual Investigator Award for Cancer in Children and Adolescents)
$2.4 million for Arvind Dasari's research in Circulating Tumor DNA- Defined Minimal Residual Disease in Colorectal Cancer (Individual Investigator Research Award for Clinical Translation)
Targeting Alterations of the NOTCH! Pathway in Head and Neck Squamous Cell Carcinoma (HNSCC)(Faye Johnson) - $1.2 million (Individual Investigator Research Award for Clinical Translation)
$2.07 million for Florencia McAllister's research in Modulating the Gut- Tumor Microbial Axis to Reverse Pancreatic Cancer Immunosuooression (Individual Investigator Research Award for Clinical Translation)
$2 million to recruit Eric Smith, MD, PhD, to The University of Texas MD Anderson Cancer Center from Memorial Sloan Kettering Cancer Center (Recruitment of First-Time, Tenure-Track Faculty Members Award)
$2 million for Karen Basen-Engquist's research in Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

Seed Awards for Product Development Research

Houston and Boston-based Asylia Therapeutics's Jeno Gyuris was granted $3 million for its development of a Novel Approach to Cancer Immunotherapy by Targeting Extracellular Tumor- derived HSP70 to Dendritic Cells
Houston-based Barricade Therapeutics Corp.'s Neil Thapar was granted $3 million for its development of a First-In-Class Small Molecule, TASIN, for Targeting Truncated APC Mutations for the Treatment of Colorectal Cancer (CRC)

Rice students earn the most upon graduation, according to a new study. Photo courtesy of Rice University

This Houston university's new grads make the most money in the state

Income outcome

A new study calculates that students who attend Rice University have the highest initial earning potential among Texas graduates.

Financial website SmartAsset ranked the top 10 Texas colleges where students earn the best average starting salaries upon graduation. Rice tops the list, with students earning an average of $65,700 in their first job out of school.

The salary ranking is part of a larger SmartAsset study that looked at five factors — tuition, student living costs, scholarship and grant offerings, retention rate, and starting salary — to determine the best value colleges and universities. Rice also comes in No. 1 on that list. Rice students pay an average of $42,253 tuition and $16,000 in living costs; that's offset by an average of $36,192 in scholarships and grants.

These findings come in an era where students are taking on staggering amounts of debt. The average annual growth rate for the cost to attend a four-year university between 1989 and 2016 was 2.6 percent per year, compared to a low 0.3 percent annual growth in wages, according to SmartAsset.

Another Houston-area school follows at No. 2 on the salary report. Students of The University of Texas Medical Branch in Galveston earn an average of $60,000 upon entering the workforce. (Tuition and living costs were not released for that school, nor were scholarship and grant numbers.)

Here is the breakdown of the 10 Texas schools with the highest starting salaries:

Rice University, Houston, $65,700
The University of Texas Medical Branch, Galveston, $60,000
The University of Texas Health Science Center, San Antonio, $57,800
Texas A&M University, College Station, $57,200
The University of Texas, Austin, $56,900
LeTourneau University, Longview, $55,300
Southern Methodist University, Dallas, $55,000
Prairie View A&M University, Prairie View, $54,300
The University of Texas at Dallas, Richardson, $53,600
Texas Tech University, Lubbock, $49,375

---

This story originally appeared on CultureMap.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

$1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
$922 million for the University of Houston System
$167 million for Texas Southern University
$10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
Created the Lake Houston Dredging and Maintenance District
Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME